Contineum Therapeutics, Inc. — All Filings
147 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
S-1
S-1/A
S-3
S-8
SC 13G
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| CORRESP | — | 0001437749-25-018028 | May 21, 2025 | — |
| UPLOAD | — | 0000000000-25-005357 | May 20, 2025 | — |
| SCHEDULE 13G/A | — | 0000950170-25-072735 | May 15, 2025 | — |
| S-8 | FORM S-8 | 0001437749-25-016878 | May 14, 2025 | — |
| 8-K | FORM 8-K | 0001437749-25-016877 | May 14, 2025 | — |
| S-3 | FORM S-3 | 0001437749-25-016871 | May 14, 2025 | — |
| 10-Q | FORM 10-Q | 0001437749-25-016835 | May 14, 2025 | Mar 31, 2025 |
| ARS | ARS | 0001437749-25-013556 | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | FORM DEFA14A | 0001437749-25-013532 | Apr 29, 2025 | — |
| DEF 14A | FORM DEF 14A | 0001437749-25-013528 | Apr 29, 2025 | Jun 26, 2025 |
| 4 | FORM 4 | 0001437749-25-013340 | Apr 28, 2025 | — |
| 3 | FORM 3 | 0001437749-25-013335 | Apr 28, 2025 | — |
| 8-K | FORM 8-K | 0001437749-25-013334 | Apr 28, 2025 | — |
| 4 | FORM 4 | 0001437749-25-008003 | Mar 17, 2025 | Mar 14, 2025 |
| 3 | FORM 3 | 0001437749-25-008001 | Mar 17, 2025 | Mar 14, 2025 |
| 8-K | FORM 8-K | 0001437749-25-007998 | Mar 17, 2025 | Mar 14, 2025 |
| S-8 | FORM S-8 | 0001437749-25-006459 | Mar 6, 2025 | — |
| 10-K | FORM 10-K | 0001437749-25-006458 | Mar 6, 2025 | Dec 31, 2024 |
| 8-K | FORM 8-K | 0001437749-25-006457 | Mar 6, 2025 | — |
| SCHEDULE 13G/A | — | 0000950170-25-021230 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001104659-25-013643 | Feb 14, 2025 | — |
| 4 | FORM 4 | 0001437749-25-002436 | Jan 31, 2025 | — |
| 4 | FORM 4 | 0001437749-25-002435 | Jan 31, 2025 | — |
| 4 | FORM 4 | 0001437749-25-002431 | Jan 31, 2025 | — |
| 4 | FORM 4 | 0001437749-25-002429 | Jan 31, 2025 | — |
| 4 | FORM 4 | 0001437749-25-002424 | Jan 31, 2025 | — |
| 4 | FORM 4 | 0001437749-24-036349 | Nov 27, 2024 | Nov 25, 2024 |
| 4 | FORM 4 | 0001437749-24-035887 | Nov 20, 2024 | Nov 18, 2024 |
| 144 | — | 0001950047-24-008738 | Nov 18, 2024 | — |
| SC 13G | SC 13G | 0001104659-24-119059 | Nov 14, 2024 | — |
| 10-Q | FORM 10-Q | 0001437749-24-033616 | Nov 6, 2024 | Sep 30, 2024 |
| 8-K | FORM 8-K | 0001437749-24-033614 | Nov 6, 2024 | — |
| 4 | FORM 4 | 0001437749-24-026903 | Aug 14, 2024 | Aug 13, 2024 |
| 10-Q | FORM 10-Q | 0001437749-24-026680 | Aug 14, 2024 | Jun 30, 2024 |
| 8-K/A | FORM 8-K/A | 0001437749-24-026664 | Aug 14, 2024 | Aug 13, 2024 |
| 8-K | FORM 8-K | 0001437749-24-026385 | Aug 13, 2024 | — |
| 4 | SARAH BOYCE FORM 4 | 0001437749-24-021091 | Jun 24, 2024 | — |
| 3 | SARAH BOYCE FORM 3 | 0001437749-24-021089 | Jun 24, 2024 | — |
| 8-K | FORM 8-K | 0001437749-24-021083 | Jun 24, 2024 | Jun 21, 2024 |
| 4 | FORM 4 | 0001437749-24-019086 | Jun 3, 2024 | — |
| 3 | FORM 3 | 0001437749-24-019084 | Jun 3, 2024 | May 30, 2024 |
| 8-K | FORM 8-K | 0001437749-24-018934 | May 31, 2024 | May 24, 2024 |
| 4 | OPTION GRANT | 0001437749-24-018626 | May 29, 2024 | May 24, 2024 |
| 4 | OPTION GRANT | 0001437749-24-018625 | May 29, 2024 | May 24, 2024 |
| 4 | OPTION GRANT | 0001437749-24-018624 | May 29, 2024 | May 24, 2024 |
| 4 | OPTION GRANT | 0001437749-24-018623 | May 29, 2024 | May 24, 2024 |
| 4 | OPTION GRANT | 0001437749-24-018622 | May 29, 2024 | May 24, 2024 |
| 4 | OPTION GRANT | 0001437749-24-018621 | May 29, 2024 | May 24, 2024 |
| 4 | OPTION GRANT | 0001437749-24-018620 | May 29, 2024 | May 24, 2024 |
| 4 | OPTION GRANT | 0001437749-24-018619 | May 29, 2024 | May 24, 2024 |